Delving into the Latest Updates on CD7 CAR-T(Guangzhou Bio-gene Technology) with Synapse

Overview

Basic Info

Drug Type

Universal CAR-T

Synonyms-

Target

CD7

Mechanism

CD7 inhibitors(T-cell antigen CD7 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Precursor T-Cell Lymphoblastic Leukemia-LymphomaT-cell Acute Lymphoblastic Leukemia/Lymphoma

Inactive Indication-

Originator Organization

Guangzhou Bio-gene Technology Co., Ltd.

Active Organization

Guangzhou Bio-gene Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

SummaryCD7‐targeted chimeric antigen receptor T‐cell (CAR‐T) therapy has shown promising initial complete remission (CR) rates in patients with refractory or relapsed (r/r) T‐cell acute lymphoblastic leukaemia and lymphoblastic lymphoma (T‐ALL/LBL). To enhance the remission duration, consolidation with allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is considered. Our study delved into the outcomes of 34 patients with r/r T‐ALL/LBL who underwent allo‐HSCT after achieving CR with autologous CD7 CAR‐T therapy. These were compared with 124 consecutive T‐ALL/LBL patients who received allo‐HSCT in CR following chemotherapy. The study revealed that both the CAR‐T and chemotherapy cohorts exhibited comparable 2‐year overall survival (OS) (61.9% [95% CI, 44.1–78.1] vs. 67.6% [95% CI, 57.5–76.9], p = 0.210), leukaemia‐free survival (LFS) (62.3% [95% CI, 44.6–78.4] vs. 62.0% [95% CI, 51.8–71.7], p = 0.548), non‐relapse mortality (NRM) rates (32.0% [95% CI, 19.0–54.0] vs. 25.3% [95% CI, 17.9–35.8], p = 0.288) and relapse incidence rates (8.8% [95% CI, 3.0–26.0] vs. 15.8% [95% CI, 9.8–25.2], p = 0.557). Patients aged ≤14 in the CD7 CAR‐T group achieved high 2‐year OS and LFS rates of 87.5%. Our study indicates that CD7 CAR‐T therapy followed by allo‐HSCT is not only effective and safe for r/r T‐ALL/LBL patients but also on par with the outcomes of those achieving CR through chemotherapy, without increasing NRM.

10 Nov 2023·Leukemia & Lymphoma

Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation

Article

Author: Ni, Jingbo ; Wei, Zhijie ; Chen, Jiaqi ; Zhang, Yang ; Wang, Fang ; Wang, Tong ; Sun, Ruijuan ; Zhang, Gailing ; Zhang, Xian ; Li, Jingjing ; Lu, Peihua ; Li, Wenqian

T-acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) patients with t(8;14)(q24;q11)/TCRA/D::MYC translocation represent a rare subgroup, with an aggressive course. In our retrospective analysis of 14 patients, all were identified during refractory or relapsed stages (5 primary tumor, 9 relapse). Notably, extramedullary invasion was detected in most patients. Four exhibited STIL::TAL1 translocation, and six demonstrated CDKN2A/B gene loss. The therapeutic outcomes were notably poor for all seven patients who received only chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT); all eventually succumbed to the disease with a median OS of 3 months. In the application of CD7 CAR-T therapy in six patients, five achieved CR. Of the four patients who underwent HSCT following CAR-T therapy, all have remained disease-free. The prognosis for T-ALL/LBL patients with t(8;14) translocation remains bleak, but interventions involving CD7 CAR-T may offer a potential pathway to CR. HSCT following CAR-T could be a viable strategy for long-term survival.

14 Oct 2023·Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Allogeneic hematopoietic stem cell transplantation combined with CD7 CAR-T for the treatment of T lymphoblastic lymphoma: a case report and literature review].

Review

Author: Zhou, H Y ; Sun, Q ; Yan, D M ; Xu, L Y ; Zhou, Y ; Yao, Z H ; Xu, K L ; Sang, W ; Zhang, J L ; Yao, S N ; Zhang, Q ; Wang, X M ; Li, H J

100 Deals associated with CD7 CAR-T(Guangzhou Bio-gene Technology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	CN	Guangzhou Bio-gene Technology Co., Ltd.	01 May 2023
T-cell Acute Lymphoblastic Leukemia/Lymphoma	Phase 2	CN	Guangzhou Bio-gene Technology Co., Ltd.	01 May 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2021	Not Applicable	Carney Complex CD19 \| CD7	-	CD19 CAR-T	(czcajabvow) = gytwgkyzjg xtmbjdtqqq (rpxnpphqlc )	-	09 Jun 2021
				CD7 CAR-T	(czcajabvow) = cypemraiqf xtmbjdtqqq (rpxnpphqlc )